Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ertugliflozin - Merck/Pfizer

Drug Profile

Ertugliflozin - Merck/Pfizer

Alternative Names: MK-8835; PF-04971729; PF-4971729; STEGLATRO

Latest Information Update: 27 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Merck & Co; Pfizer
  • Class Antihyperglycaemics; Chlorobenzenes; Glycosides; Heterocyclic bicyclo compounds; Phenyl ethers; Small molecules
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Discontinued Hypertension

Most Recent Events

  • 25 Nov 2019 Launched for Type 2 diabetes mellitus in Canada, USA, Netherlands, Ireland, Poland, Denmark, Finland, Norway, United Kingdom (PO)
  • 27 Sep 2019 Phase-III clinical trials in Type 2 diabetes mellitus (In children, In adolescents) in Belgium, France, Poland, Hungary, USA (PO) (NCT04029480) (EudraCT2017-003455-35)
  • 23 Jul 2019 Merck and Pfizer plans a phase III trial for Type 2 diabetes mellitus (In children, In adolescents) in October 2019 (PO) (NCT04029480)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top